Fertility-prediction startup Celmatix seeks funding

  • Startup provides fertility-prediction software, reproductive health tests
  • Founded in 2009 by CEO Beim, Bandak
  • Just below $60 mln in financing to date

Celmatix, the health-tech startup that uses big data to improve reproductive medicine, is seeking a round of financing, Buyouts has learned.

The women’s-health startup has turned to Jefferies for financial advice on the capital raise, people familiar with the matter said. The process is expected to launch imminently, one of the people said.

Celmatix works with fertility clinics to perform genomics and diagnostics tests, collecting patient information, which is used to create personalized treatment plans for women who have difficulty getting pregnant. The startup’s predictive-analytics software is known as Polaris.

Celmatix in late 2017 launched a fertility test called Fertilome, which predicts health risks for a baby and genetic factors that may affect a woman’s ability to conceive.

The startup was founded in 2009 by CEO Piraye Yurttas Beim and Laura Towart Bandak.

Celmatix has raised just south of $60 million in total funding to date, according to Crunchbase, which lists Topspin Partners and Brainchild Holdings as existing investors.

The women’s-health and reproductive-health markets have seen increasing momentum from the private equity community in recent years.

Among notable activity, growth-focused PE shop TA Associates in 2015 invested in Colorado Center for Reproductive Medicine. CCRM operates a network of fertility clinics that offer treatments ranging from basic infertility care to advance in vitro fertilization.

Warburg Pincus late last year secured a piece of the China market through its investment in Jinxin IVF.

Others that have taken a liking to reproductive health include Lee Equity Partners, which in 2016 formed Prelude Fertility, an Atlanta fertility clinic and frozen egg bank, in partnership with entrepreneur Martín Varsavsky. Varsavsky and Lee committed up to $200 million in equity funding in the asset.

MTS Health Investors in 2015 formed Ovation Fertility, a network of assistive reproductive technology laboratories that perform treatment and testing for infertility patients.

In other areas of the women’s-health market, Lindsay Goldberg in October 2017 invested in obstetrics company Women’s Care Florida.

The deal followed Ares Management’s sale of OB Hospitalist, one of the largest such platforms in the country, to Gryphon Investors, in a deal valued at close to $625 million, Buyouts reported at the time.

Representatives of Celmatix and Jefferies declined comment.

Action Item: Learn more about Celmatix